Commitments

6 Months Ended

Jun. 30, 2016

Commitments.

Commitments

9. Commitments

In June 2015, we entered into a contract with a third party for clinical manufacturing supplies to support our ongoing clinical trials for ganaxolone.  Full delivery occurred during the first two quarters of 2016.  We recorded $1.7 million and $3.0 million of research and development expense in the three and six months ended June 30, 2016, respectively, related to these supplies, of which $2.0 million is included in accrued expenses as of June 30, 2016..